Tasquinimod

Tasquinimod for the Treatment of Relapsed or Refractory Myeloma

What's the purpose of the trial?

This study is the first study of tasquinimod, an inhibitor of S100A9, in patients with multiple myeloma.

Trial status

Accepting patients

Phase
Phase 1
Enrollment
34
Last Updated
2 months ago
Patient Screener

Participating Centers

There is one center participating in this trial. Enter a location below to view the distance.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Dexamethasone is a corticosteroid that prevents the release of substances in the body that cause inflammation, and is given in conjunction with some cancer treatments.
  • Ixazomib is a kind of medication called a proteasome inhibitor that interferes with the growth of cancer cells by blocking some of the enzymes needed for cell growth. Ixazomib is used in the treatment of multiple myeloma.
  • Lenalidomide is an oral immunomodulatory drug that may help the immune system kill cancer cells. It may also prevent the growth of new blood vessels that tumors need to grow.
  • Tasquinimod is an oral S100A9 inhibitor being evaluated in multiple myeloma.

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.